Tempus AI, Inc. (NASDAQ:TEM - Get Free Report) CAO Ryan Bartolucci sold 1,540 shares of the business's stock in a transaction on Tuesday, November 17th. The stock was sold at an average price of $63.02, for a total transaction of $97,050.80. Following the completion of the transaction, the chief accounting officer owned 59,264 shares of the company's stock, valued at approximately $3,734,817.28. This trade represents a 2.53% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.
Tempus AI Stock Performance
NASDAQ:TEM traded down $4.01 during trading hours on Thursday, reaching $59.61. 5,290,938 shares of the company's stock were exchanged, compared to its average volume of 6,229,094. Tempus AI, Inc. has a 1-year low of $40.77 and a 1-year high of $89.09. The company has a quick ratio of 2.48, a current ratio of 2.61 and a debt-to-equity ratio of 2.70. The firm has a market capitalization of $10.87 billion, a price-to-earnings ratio of -56.24 and a beta of 3.61. The company has a 50-day moving average of $72.87 and a 200 day moving average of $57.56.
Tempus AI (NASDAQ:TEM - Get Free Report) last issued its earnings results on Monday, November 2nd. The company reported $0.07 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.09) by $0.16. Tempus AI had a negative net margin of 12.54% and a negative return on equity of 47.00%. The company had revenue of $411.54 million during the quarter, compared to analysts' expectations of $409.39 million. During the same period last year, the company posted ($0.46) earnings per share. The firm's quarterly revenue was up 23.1% compared to the same quarter last year. Research analysts anticipate that Tempus AI, Inc. will post -1.20 EPS for the current year.
Wall Street Analysts Forecast Growth
A number of analysts recently weighed in on TEM shares. BTIG Research upped their price target on shares of Tempus AI from $80.00 to $100.00 and gave the stock a "buy" rating in a research report on Tuesday, November 3rd. Rothschild & Co Redburn initiated coverage on Tempus AI in a research note on Tuesday, September 8th. They issued a "neutral" rating and a $67.00 target price for the company. Robert W. Baird lifted their price objective on shares of Tempus AI from $85.00 to $92.00 and gave the company an "outperform" rating in a research note on Tuesday, November 3rd. Wall Street Zen raised shares of Tempus AI from a "sell" rating to a "hold" rating in a research report on Saturday, July 25th. Finally, Jefferies Financial Group upgraded shares of Tempus AI from an "underperform" rating to a "hold" rating and upped their target price for the company from $35.00 to $70.00 in a research note on Tuesday, November 3rd. Eleven investment analysts have rated the stock with a Buy rating, ten have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company has a consensus rating of "Hold" and an average price target of $79.37.
Read Our Latest Stock Report on Tempus AI
Latest Tempus AI News
Investors following TEM have been watching these news items:
- Positive Sentiment: Tempus and AstraZeneca extended their strategic services agreement through a fifth amendment. The expanded relationship may support Tempus’s data and services business and validates its capabilities with a major pharmaceutical partner; the supplied summaries do not specify the financial terms. Tempus AI and AstraZeneca Extend Strategic Services Agreement
- Positive Sentiment: HC Wainwright reaffirmed its Buy rating and $85 price target, indicating substantial potential upside from the cited $59.61 reference price. This is analyst opinion, not a guarantee of performance. HC Wainwright rating information
- Neutral Sentiment: Comparisons with Natera and Grail emphasize Tempus’s AI-enabled data ecosystem, while noting Natera’s growth and positive free cash flow and Grail’s Galleri cancer test trials. These articles provide competitive context rather than a new company-specific catalyst. Natera vs. Tempus AI Grail vs. Tempus AI
Institutional Inflows and Outflows
A number of large investors have recently added to or reduced their stakes in the stock. Guardian Partners Inc. raised its holdings in shares of Tempus AI by 8.3% during the third quarter. Guardian Partners Inc. now owns 2,600 shares of the company's stock worth $213,000 after acquiring an additional 200 shares in the last quarter. Kestra Private Wealth Services LLC increased its position in Tempus AI by 1.4% in the 3rd quarter. Kestra Private Wealth Services LLC now owns 18,685 shares of the company's stock worth $1,530,000 after purchasing an additional 257 shares during the last quarter. V Square Quantitative Management LLC acquired a new position in Tempus AI in the 3rd quarter worth about $27,000. ProShare Advisors LLC raised its stake in shares of Tempus AI by 5.9% during the 3rd quarter. ProShare Advisors LLC now owns 6,500 shares of the company's stock worth $532,000 after purchasing an additional 360 shares in the last quarter. Finally, Cyndeo Wealth Partners LLC lifted its holdings in shares of Tempus AI by 6.7% during the 3rd quarter. Cyndeo Wealth Partners LLC now owns 6,412 shares of the company's stock valued at $525,000 after buying an additional 400 shares during the last quarter. 24.22% of the stock is currently owned by institutional investors.
About Tempus AI
(
Get Free Report)
Tempus AI is a technology company focused on applying data and artificial intelligence to healthcare, with an emphasis on precision medicine. Its platform combines clinical and molecular data to help physicians make more informed treatment decisions and support life-sciences research. The company provides genomic sequencing and other diagnostic testing, software tools for analyzing patient data, and services that help identify clinical trial opportunities. Its work spans oncology and other areas of medicine, and it collaborates with healthcare providers and pharmaceutical and biotechnology companies.
Featured Articles

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Tempus AI, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Tempus AI wasn't on the list.
While Tempus AI currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.